Report recommends that Ottawa run a centralized, first-payer public drug plan

Note : Ce résumé a été produit à partir de la nouvelle sous Lire l'article ci-dessous. Si vous avez des questions, prière de les acheminer à cette source.

Viabilité
janvier 10, 2019

A report from the Broadbent Institute contends there's nearly universal appeal for the idea of a national pharmacare program and outlines two possible strategies for achieving this goal. The first is for Ottawa to provide transfers to the provinces and territories, who'd set up their own public drug plan within parameters set federally. The institute's preferred option is for a nationally-funded and operated system, given Ottawa's jurisdiction over drug safety, price regulation and patent protection.

Lire l'article